The PennZone

  • Home
  • Business
  • Construction
  • Real Estate
  • Technology
  • Non-profit
  • Travel
  • Music
  • Legal

ExpressCells to Present in BIO Start-Up Stadium Next Week
The PennZone/10070540

Trending...
  • Platinum Car Audio LLC Focuses on Customer-Driven Vehicle Audio and Electronics Solutions
  • Mecpow M1: A Safe & Affordable Laser Engraver Built for Home DIY Beginners
  • Postmortem Pathology Expands Independent Autopsy Services Across Colorado
Company is one of 30 selected for prestigious competition. During BIO Digital Week, attendees can watch timely, on-demand pitches and meet with ExpressCells via BIO's One-on-One Partnering.

PHILADELPHIA - PennZone -- ExpressCells, Inc. (ExpressCells), a privately-owned genetic engineering company that creates knock-in cell lines for drug discovery, will be one of the finalists presenting in the Start-Up Stadium during BIO Digital Week.

"We are honored to be selected by the judges as one of the finalists for Start-Up Stadium. We hope that all BIO Digital Week attendees view our presentation, which will be available on demand via the meeting platform."

Start-Up Stadium provides an exciting and interactive experience where key stakeholders of the early-stage life science community, investors, and strategic partners provide feedback and judge 6 minute pitches presented by start-up biotech companies. During BIO Digital Week, attendees can watch ExpressCells' pitch on-demand and meet with the company via BIO's One-on-One Partnering.

More on The PennZone
  • Summit Appoints Javier Cabeza as Data, AI, and Analytics Practice Lead
  • TrueNorth Wellness Services is Excited to Participate in Give Local York
  • March Is Skiing's Smartest Buying Window
  • Hope Survives Launches The Hope Collective, A Curated Publication Centering Lived Experience After Brain Injury
  • Cancun Airport Transportation Expands Fleet Ahead of Record Passenger Growth at Cancun International Airport

"ExpressCells is excited to be part of BIO Digital Week," Mr. Handel continued. "We hope to gain valuable feedback and to meet with both potential customers and potential investors.

About ExpressCells

ExpressCells is a private biotechnology company based in Philadelphia, PA. Its propriety genome editing technology, in combination with CRISPR/Cas9, creates advanced, knock-in cell line up to 75% faster than older processes. This technology allows ExpressCells to insert up to three genes into the same cell line.

ExpressCells' first knock-in cell lines code for bioluminescent and fluorescent proteins. These allow scientists to more see the results of their experiments in real time. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines. For more information, visit www.xpresscells.com.

Contact
Matthew Handel
***@xpresscells.com
+1 (484) 483-6759


Source: ExpressCells, Inc.

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Kilmaine Saints to Record Live Album at XL Live
  • CCHR: While Damaging Antipsychotics Win Approval, Proven Non-Drug Alternatives Remain Ignored
  • Arcuri Group Announces Long‑Term Partnership with WakeMed Health & Hospitals to Deliver Situational Awareness and De‑escalation Training
  • KDG Announces Acquisition of Square Foot Consultants, Expanding Business and Technology Expertise
  • Colonial Nissan Service Named Top 5 Auto Repair in Feasterville-Trevose for 2025
  • At 25, She Became One of the Youngest AAPI Female Founders to Win One of the World's Most Prestigious Design Awards for a Lamp That Makes You Smile
  • Juego Studios Extends Full-Cycle Game Development & Outsourcing Capabilities to the UAE Market
  • VENUS Goes Live on CATEX Exchange As UK Financial Ltd Activates The Premier Division Of The Maya Meme's League
  • Atlanta Tech Founder Seeks Clarity on Intellectual Property and Innovation Policy
  • Purple Heart Recipient Honored by Hall of Fame Son In Viral Tribute Sparking National Conversation on Service Fatherhood, Healing and Legacy
  • Maronda Homes Leverages Power of AI to Automate, Accelerate Home Warranty Claims Process
  • ATS (The Athletic Trainer System) Releases comprehensive student health features
  • Amicly Launches as a Safety-First Social App Designed to Help People Build Real, Meaningful Friendships
  • Primeindexer Google indexing platform launched by SEO Danmark APS
  • Kaltra Introduces New Downward-Spraying Distribution Technology to Boost Microchannel Evaporator Performance
  • Talentica Announces Winners of Multi-Agent Hackathon 2026
  • Special Alert: Undervalued Opportunity: IQSTEL (N A S D A Q: IQST) Positioned for Explosive Multi-Year Growth
  • Triple-Digit Growth, Strategic N A S D A Q Uplist, Plus A Scalable Healthcare Rollout Model: Stock Symbol: CDIX
  • Vesica Health Receives FDA Breakthrough Device Designation for AssureMDx
  • Lineus Medical's SafeBreak® Vascular Added to Alliant GPO Contract

Popular on PennZone

  • Still Using Ice? FrostSkin Reinvents Hydration
  • OneVizion Announces Next Phase of Growth as Brad Kitchens Joins Board of Directors
  • Cold. Clean. Anywhere. Meet FrostSkin
  • Luxury Lake-View Home Launches in Kissimmee's Bellalago community, Offering Privacy, Space, and Florida Resort-Style Living
  • Ice Melts. Infrastructure Fails. What Happens to Clean Water?
  • Roshni Online Services Unveils Plans for Innovative Digital Consultation Platform
  • Wala Blegay to Announce Run for Congress in Maryland's 5th District on Feb. 4
  • Jacob Emrani's Annual "Supper Bowl" Expected To Donate Thousands Of Meals
  • Nest Finders Property Management Named #1 in Jacksonville and Ranked #99 Nationwide
  • Mend Colorado Launches Revamped Sports Performance Training Page

Similar on PennZone

  • National Expansion Ignited Across Amazon $AMZN, Chewy $CHWY & Walmart $WMT: NDT Pharmaceuticals, Inc. (Stock Symbol: NDTP) $NDTP
  • Vesica Health Receives FDA Breakthrough Device Designation for AssureMDx
  • Postmortem Pathology Expands Independent Autopsy Services in Kansas City
  • ClearSight Therapeutics Signs LOI with Covalent Medical for $60M Multi-Channel OTC Eye Care Partnership
  • Capsadyn® Launches on Amazon, Offering Non-Burning Capsaicin Pain Relief
  • FDA Meeting Indicates a pivotal development that could redefine the treatment landscape for suicidal depression via NRx Pharmaceuticals: $NRXP
  • Parkway Prosthodontics Achieves Breakthrough Full-Arch Reconstruction Case
  • Postmortem Pathology Expands to Phoenix: Bringing Families Answers During Their Most Difficult Moments
  • EPP Pricing Platform announces leadership transition to support long-term growth and continuity
  • Stipenda Appoints David Epstein as Chief Operating Officer
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us